1
Mohamed SKIBA Mohamed SKIBA
Mohamed Skiba, Malika Lahiani, Frederic Bounoure, Pierre Dechelotte: Association of Oleaginous Substance With a Mixture of at Least Two Cyclodextrins. In Cyclo, Harness Dickey & Pierce, May 21, 2009: US20090130218-A1

The invention concerns a mixture of inclusion complexes comprising or consisting of (1) at least two different cyclodextrins selected among alpha-, beta- and gamma cyclodextrin and/or derivatives thereof, in particular derivatives thereof modified by primary and/or secondary hydroxyl groups, and (2) ...


2
Mohamed SKIBA Mohamed SKIBA
Skiba Mohamed, Skiba Malika, Bounoure Frédéric, Dechelotte Pierre: (Fr) Composition homogene et stable, riche en substances oleagineuses a base dun produit laitier, son procede de preparation et ses utilisations, (En) Homogeneous and stable composition rich in oleaginous substances based on a milk product, method for the preparation thereof and uses thereof. In Cyclo, Skiba Mohamed, Skiba Malika, Bounoure Frédéric, Dechelotte Pierre, BREDEMA, December 18, 2008: WO/2008/152226

(EN) The present invention relates to a stable and homogeneous milk composition based on milk comprising at least one cyclodextrin and at least one oleaginous substance. It also relates to the preparation thereof and also to products prepared therefrom, such as food compositions, powders, medicinal ...


3
Mohamed SKIBA Mohamed SKIBA
Skiba Mohamed, Skiba Malika, Bounoure Frederic, Dechelotte Pierre: Composition homogene et stable, riche en substances oleagineuses a base dun produit laitier, son procede de preparation et ses utilisations.. In Cyclo Soc Par Actions Simpl, November 14, 2008: FR2915901-A1

L'invention a pour objet une composition lactée stable et homogène à base de lait comprenant au moins une cyclodextrine et au moins une substance olagineuse. Elle concerne aussi sa préparation ainsi que des produits préparés à partir de celle-ci comme des compositions alimentaires, poudres, alicamen ...


4

5

6
James Doherty
Dorn Conrad P, Finke Paul E, Maccoss Malcolm, Doherty James B, Shah Shrenik K, Hagmann William K: New substituted azetidinones as anti-inflammatory and antidegenerative agents.. Merck & Co, April 22, 1992: EP0481671-A1 (40 worldwide citation)

New substituted azetidinones of the general formula (A') which have been found to be potent elastase inhibitors and thereby useful anti-inflammatory and antidegenerative agents are described. e


7
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Stéphane De Lombaert, Taeyoung Yoon, Xiaozhang Zheng: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, July 28, 2009: US07566712 (6 worldwide citation)

Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathologic ...


8
Stéphane De Lombaert
DE LOMBAERT Stéphane, LIU Weimin, LO Ho Yin, NEMOTO Peter Allen: INHIBITEURS BENZIMIDAZOLE DE PRODUCTION DE LEUCOTRIÈNES, BENZIMIDAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION. BOEHRINGER INGELHEIM INTERNATIONAL, DE LOMBAERT Stéphane, LIU Weimin, LO Ho Yin, NEMOTO Peter Allen, MORRIS Michael P, May 10, 2012: WO/2012/061169 (1 worldwide citation)

The present invention relates to compounds of formula (IA), (IB) and (IC) and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of var ...


9
Toufike Kanouni
Qing Dong, Toufike Kanouni, Michael B Wallace: MAPK/ERK kinase inhibitors. Takeda Pharmaceutical Company, David M Stemerick, Mitchell R Brustein, September 20, 2011: US08022057 (1 worldwide citation)

Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using sa ...


10
Tarran Jones
LAROSA GREGORY J, HORVATH CHRISTOPHER, NEWMAN WALTER, JONES S TARRAN, O BRIEN SIOBHAN, O KEEFE THERESA: ANTICORPS HUMANISES ANTI-CCR2 ET PROCEDES DUTILISATION DE CES ANTICORPS, HUMANIZED ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR. MILLENNIUM PHARMACEUTICALS, MILLENNIUM PHARMACEUTICALS, GOWLING LAFLEUR HENDERSON, May 21, 2013: CA2399080

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor (2) (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the inte ...



Click the thumbnails below to visualize the patent trend.